Agranulocytosis induced by sulphonamide or dapsone (44-diaminodiphenylsulphone -DDS) is characterized by a low concentration or absence of granulocytes due to sulfone cytotoxicity effects on bone marrow and mononuclear cells. We report a 61-year-old Caucasian female patient, resident in Juazeiro, state of Bahia, Brazil, complaining of a spot on the right elbow, which appeared 1 year before. Physical examination revealed a single hypochromic patch, approximately 1cm in diameter, with micropapular edges and absent thermal sensitivity. With a diagnosis of tuberculoid leprosy, we started a MDT regimen for paucibacillary leprosy. At day 14 after the first administration, the patient presented with adynamia, exertional dyspnea, normochromic normocyt-
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DDS is a structural analogue of para-aminobenzoic acid (PABA) that acts as a competitive inhibitor of the enzyme dihydropteroate synthase in the folate pathway. It has anti-inflammatory, antibacterial, antiprotozoal, and antifungal activities. Used since 1943 to treat leprosy, it is also indicated for the treatment of malaria, rheumatoid arthritis, granuloma annulare, dermatitis herpetiformis, and other vesiculobullous diseases. DDS adverse effects include hemolytic anemia, methemoglobinemia, gastritis, headache, agranulocytosis, hepatitis, peripheral neuropathy, nephrotic syndrome, dapsone syndrome, among others. 1, 2 DDS is part of the multidrug therapy (MDT) used to treat leprosy. The regimen is a combination of rifampicin (supervised monthly dose of 600mg) and dapsone (supervised monthly dose of 100mg and 100mg/daily) for paucibacillary patients, with the addition of clofazimine (supervised monthly dose of 300mg and 50mg/ daily) for multibacillar patients. 2 We report a 61-year-old Caucasian female patient, resident in Juazeiro, state of Bahia, Brazil, complaining of a spot on the right elbow, which appeared 1 year before. Physical examination revealed a single hypochromic patch, approximately 1cm in diameter, with micropapular edges and absent thermal sensitivity. With a diagnosis of tuberculoid leprosy, we started a MDT regimen for paucibacillary leprosy. At day 14 after the first administration, the patient presented with adynamia, exertional dyspnea, normochromic normocyt- Figure 3C shows the evolution of the clinical features, compatible with FFA.
As already reported by Pirmez et al., although the pseudo "fringe sign" can occur in patients with FFA, biopsies show the characteristic pattern of LPP, which may make diagnosis challenging. 5 In the reported cases, the presence of facial papules and thinning eyebrows contributed to the diagnosis of FFA, in detriment of LPP with alopecia plaques. In addition, the loss of vellus hair in the frontal region was not observed initially, but a loss after the frontal implantation line, affecting the terminal hairs of that region. Unlike TA, this fringe slowly becomes more rarefied, eventually leading to some vellus hair loss in the region in a later phase, with a scarring, shiny appearance and absence of follicular ostia to trichoscopy.
A study with a greater number of reported cases of this clin- Agranulocytosis is an adverse effect of dapsone manifested as bone marrow suppression, which is caused by the formation of antibodies against neutrophil progenitor cells, decreasing the granulocyte formation. Another possible mechanism is the sensitization to the drug that forms hydroxylamine, a toxic metabolite of dapsone responsible for methemoglobinemia and hemolysis. 3 For the treatment of leprosy, the risk of developing DDS-induced agranulocytosis is about 25-33 times higher because of reduced immunity and high dosage of the drug, as compared, for example to the treatment of malaria with an incidence between 1:10,000 and 1: 20,000 is reported. 4 reported cases in male patients; our report is in agreement with the literature in relation to the female predilection. 5 In relation to age, our report agrees Bhat and Radhakrishnan (2003), 4 showing a higher incidence around 60 years of age.
According to Mishra and Chhetia (2006) , 3 Carneiro et al.
(2011), 5 and our report, agranulocytosis occurs between 3 weeks and 3 months after the onset of the MDT. 5 In the literature and in our case, patients started MDT to treat agranulocytosis, but DDS had to be discontinued due to side effects. The treatments continued with antibiotic therapy and filgrastim revealing leucometric and clinical improvement in a few days, 5 except for the patient followed by Bhat and Radhakrishnan (2003), 4 who died.
After clinical improvement, some patients had their MDT altered for ofloxacin, clofazimine, and minocycline, with each drug introduced at 30-day intervals, or for rifampicin and clofazimine, as in our report. 
